Heart Transplant Failure and Rejection Clinical Trial
Official title:
Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
The study objective is to demonstrate that rejection surveillance of heart transplant recipients with Prospera dd-cfDNA is non-inferior to rejection surveillance with endomyocardial biopsy and histology in the first post-transplant year.
Subjects will be enrolled into the study while on the transplant waiting list prior to heart transplantation. All subjects will follow the center's standard of care surveillance schedule from transplant through 4 weeks post-transplantation. EMB during this phase is expected to occur roughly weekly. Subjects will be randomized in a 1:1 ratio 30 days (± 7 days) post-transplant to Prospera surveillance (Study Group) versus EMB surveillance (Control Group, standard clinical care). Rejection surveillance (Prospera testing in the Study Group and EMB in the Control Group) will be performed at times corresponding to the institutional standard of care schedule for rejection surveillance. Study Group: Prospera Surveillance (300 Subjects) Subjects will undergo Prospera testing at times corresponding to the institution's graft surveillance schedule. Prospera test results will be provided to the clinical team. Prospera cfDNA level < 0.15% will be interpreted as negative and a surveillance EMB will be omitted. Prospera cfDNA ≥ 0.15% will be followed by EMB. A for-cause EMB can be done per the clinical team's discretion at any time. Control Group: EMB Surveillance (standard of care) (300 Subjects) Subjects will undergo surveillance EMB per the institution's standard clinical care. The study intervention will be during the first 12 months post-transplant. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03102125 -
Allograft Dysfunction in Heart Transplant
|
Phase 4 | |
| Active, not recruiting |
NCT04380311 -
Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant
|
N/A | |
| Completed |
NCT02109575 -
Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
|
||
| Not yet recruiting |
NCT06414603 -
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
|
N/A | |
| Completed |
NCT04610320 -
Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
|
Phase 1 | |
| Active, not recruiting |
NCT03386539 -
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
|
Phase 3 | |
| Recruiting |
NCT03499197 -
Heart TIMING - Heart Transplantation IMagING
|
||
| Recruiting |
NCT03538509 -
Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
|
||
| Recruiting |
NCT03050892 -
Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation
|
N/A | |
| Active, not recruiting |
NCT03373279 -
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
|
||
| Recruiting |
NCT05994274 -
A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
|
||
| Active, not recruiting |
NCT03575910 -
HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
|
||
| Not yet recruiting |
NCT06453148 -
Brazilian Clinical Registry of Heart Transplantation
|
||
| Withdrawn |
NCT04088903 -
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
|
Phase 1 |